If I need rhythm control, what options besides ablation and amiodarone exist?

The evidence base for rhythm control options beyond ablation and amiodarone is thin on long-term, all-cause outcomes, and what exists is largely short-term or surrogate.

The records retrieved here focus on a single narrow question: whether pre-procedural atrial natriuretic peptide (ANP) levels predict left atrial reverse remodeling after catheter ablation for atrial fibrillation [1]. That study of 104 patients found that baseline ANP and maintenance of sinus rhythm independently predicted a 15% or greater reduction in left atrial volume index at 6 months [1]. It tells you nothing about drug alternatives, and it does not compare any rhythm-control strategy against another. It is evidence about a biomarker, not about treatment options.

What the records do not contain is any trial of antiarrhythmic drugs other than amiodarone, any comparison of rate versus rhythm control, any head-to-head of flecainide, propafenone, sotalol, dofetilide, or dronedarone against ablation, and no long-term safety data for any of them. The absence is structural: the retrieved literature is a single biomarker study, so the question as asked is simply not answerable from these records.

What can be said from general clinical knowledge, clearly outside these records, is that the common alternatives to amiodarone and ablation are class IC agents (flecainide, propafenone) for structurally normal hearts, class III agents (sotalol, dofetilide, dronedarone) with varying safety profiles, and that dronedarone carries a boxed warning for worsening heart failure in certain patients. But naming those mechanisms is not the same as having evidence for them here. The honest verdict: the evidence base for non-amiodarone, non-ablation rhythm control is not in this retrieval, and no safety or efficacy claim about those drugs can be grounded in it.

Confidence: high that the retrieved records do not answer the question; low that any specific alternative is superior, because no comparative trial was retrieved.